PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.21%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
40.44%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
42.50%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
40.54%
EPS growth of 40.54% while CRVO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
40.54%
Diluted EPS growth of 40.54% while CRVO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
0.40%
Share change of 0.40% while CRVO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.40%
Diluted share change of 0.40% while CRVO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
51.97%
OCF growth above 1.5x CRVO's 0.52%. David Dodd would confirm a clear edge in underlying cash generation.
51.97%
FCF growth above 1.5x CRVO's 0.52%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while CRVO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.95%
OCF/share CAGR of 95.95% while CRVO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
79.78%
OCF/share CAGR of 79.78% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
21.40%
3Y OCF/share CAGR under 50% of CRVO's 58.45%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
95.64%
10Y net income/share CAGR of 95.64% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
74.54%
Net income/share CAGR of 74.54% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
42.66%
3Y net income/share CAGR 50-75% of CRVO's 69.86%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
160.55%
Equity/share CAGR of 160.55% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2.24%
Equity/share CAGR of 2.24% while CRVO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-69.25%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y dividend/share CAGR while CRVO stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-14.61%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.07%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-50.78%
Our R&D shrinks while CRVO invests at 38.27%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.70%
We cut SG&A while CRVO invests at 4.76%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.